External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Cipla reported the highest-ever US business to the tune of $204 Mn (+5% QoQ), which was majority led by better execution in the base business and a higher-than-expected revenue contribution from gRevlimid in the last quarter.</li><li>gLanreotide gained market share (MS) to 17% while gAlbuterol maintain MS of ~20%.</li><li>gAdvair is delayed by almost one year and its manufacturing may go to overseas facilities.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Cipla reported the highest-ever US business to the tune of $204 Mn (+5% QoQ), which was majority led by better execution in the base business and a higher-than-expected revenue contribution from gRevlimid in the last quarter.gLanreotide gained market share (MS) to 17% while gAlbuterol maintain MS of ~20%.gAdvair is delayed by almost one year and its manufacturing may go to overseas facilities.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

CIPLA Ltd - Positive Outlook Despite Regulatory Challenges

Cipla Ltd

CIPLA Ltd - Positive Outlook Despite Regulatory Challenges